ACCESS Newswire
22 Nov 2022, 19:25 GMT+10
UPPSALA, SE / ACCESSWIRE / November 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that results from a study using the DiviTum® TKa blood test will be presented at the world's largest breast cancer symposium, SABCS, on December 8. The results support using DiviTum® TKa to predict the efficacy of CDK4/6 inhibitors in metastatic breast cancer.
'These results further strengthen the robustness of clinical evidence for use of the DiviTum® TKa test in metastatic breast cancer. Measuring TKa was done retrospectively after the study was completed and confirms the role of baseline TKa as a new marker for patient stratification. We look forward to helping patients by bringing DiviTum® TKa to market to provide a tool for physicians to better stratify and monitor patients,' said Anders Rylander, CEO of Biovica.
'These results support using DiviTum® TKa as a tool to stratify metastatic breast cancer patients when initiating therapy and to identify patients with the best pre-requisites for improved survival during CDK4/6 inhibitor treatment,' said Dr. Amelia McCartney, BSc, BA (Hons), MBBS, FRACP, first author and medical oncologist at Monash Health, Melbourne, Australia.
About the MA38 study
The study called MA38 was conducted by the Canadian Cancer Trials Group (CCTG) and investigated two different dosing schedules of the CDK4/6 inhibitor treatment palbociclib. Thymidine Kinase activity (TKa), as measured by the DiviTum® TKa assay, was used as a predictive biomarker to identify patients with a long duration on treatment and an extended overall survival in women with previously diagnosed HR-positive metastatic breast cancer (MBC).
180 women participated in the study and provided blood (serum) samples for DiviTum TKa analysis at baseline and after 12 and 24 weeks of palbociclib treatment. At baseline, the DiviTum TKa test identified patients who would go on to have a prolonged progression-free survival: patients with low TKa values (< median) had significantly longer progression-free survival than those with high (> median) TKa values, 16.3 vs 5.5 months (HR=2.43; 95% CI, 1.6-3.7; p<0.001). After 12 months, overall survival rate was 68% in patients with high baseline TKa vs 92% with low TKa. Evaluating samples drawn at 12 weeks into treatment demonstrated that high TKa values were significantly associated with worse overall survival (HR 2.0; 95% CI, 1.0- 4.0; p=0.03), with a similar trend for samples drawn at week 24.
The results will be presented on December 8 at the San Antonio Breast Cancer Symposium, SABCS 2022 (December 6-10).
MA38 study (NCT02630693)
Link: https://clinicaltrials.gov/ct2/show/NCT02630693
Poster Presentation Details
The poster (P5-02-27) will be presented on December 8 at 5:00 P - 6:15 PM CT at the San Antonio Breast Cancer Symposium, SABCS 2022 (December 6-10). Session Title: Poster Session 5: Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: For Targeted Therapies
Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: [email protected]
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: 'Improved care for cancer patients.' Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com
Attachments
Biovica's DiviTum® TKa results presented at SABCS
SOURCE: Biovica International
Get a daily dose of Memphis Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Memphis Sun.
More InformationThe death toll in Friday's massive earthquake in Myanmar has risen above 150, and is expected to rise significantly. Another nine people...
WASHINGTON, D.C.: In response to soaring egg prices and supply shortages driven by a devastating bird flu outbreak, the United States...
WASHINGTON, D.C.: U.S. President Donald Trump vowed this week that more countries will be added to the Abraham Accords, the series...
TOKYO, Japan: This week, Japan's cherry blossom season officially began as experts confirmed the first blooms in Tokyo. A specialist...
CAPE TOWN, South Africa: The U.S. Embassy in South Africa said it received a list of over 67,000 people interested in refugee status...
RALEIGH, North Carolina: North Carolina's highest court has ruled that a mother and her teenage son can pursue a lawsuit over a COVID-19...
NEW YORK, New York - Renewed fears about inflation, and U.S. Donald Trump's trade policies say American markets take a deep dive Friday....
NEW YORK CITY, New York: Segway is recalling about 220,000 scooters in the U.S. because of a safety issue that can cause riders to...
BEIJING, China: As global tech firms navigate rising geopolitical tensions, China has extended a warm signal to Apple, one of its most...
NEW YORK, New York - Shares in automakers fell sharply Thursday after U.S.President Donald Trump imposed a 25 percent tariff on all...
WASHINGTON, D.C.: Federal safety regulators have launched a new investigation into Ford's best-selling F-150 pickup trucks after receiving...
WASHINGTON, D.C.:/SEOUL: Hyundai Motor Group is set to dramatically expand its U.S. footprint, with a US$20 billion investment that...